Company intelligence / Profile preview
Hangzhou Adlai Nortye Biopharma
Hangzhou, Chinaadlainortye.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Clinical-stage biotech with Phase 3 asset (buparlisib in SCCHN), Phase 1 assets (AN4005, AN8025), and preclinical/IND-ready programs in immuno-oncology and RAS-targeting therapies.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeFusion proteinAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ASK Pharm (exclusive license for AN9025 in Greater China)
Beyond the preview
Go deeper on Hangzhou Adlai Nortye Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Adlai Nortye Biopharma.